Methyl syringate

CAS No. 884-35-5

Methyl syringate ( —— )

Catalog No. M19228 CAS No. 884-35-5

Methyl syringate has a unique inhibitory activity toward aflatoxin production with a different mode of action from that of gallic acid.

Purity : 98%

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
100MG 35 In Stock
500MG 82 In Stock
1G Get Quote In Stock

Biological Information

  • Product Name
    Methyl syringate
  • Note
    Research use only, not for human use.
  • Brief Description
    Methyl syringate has a unique inhibitory activity toward aflatoxin production with a different mode of action from that of gallic acid.
  • Description
    Methyl syringate has a unique inhibitory activity toward aflatoxin production with a different mode of action from that of gallic acid. Methyl syringate from K. pictus is a specific and selective activator of hTRPA1, can regulate food intake and gastric emptying through a TRPA1-mediated pathway and, by extension, can contribute to weight suppression.
  • Synonyms
    ——
  • Pathway
    Others
  • Target
    Other Targets
  • Recptor
    hTRPA1
  • Research Area
    Others-Field
  • Indication
    ——

Chemical Information

  • CAS Number
    884-35-5
  • Formula Weight
    212.2
  • Molecular Formula
    C10H12O5
  • Purity
    98%
  • Solubility
    ——
  • SMILES
    COc1cc(cc(c1O)OC)C(=O)OC
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Kim MJ, et al. PLoS One. 2013 Aug 21;8(8):e71603.
molnova catalog
related products
  • Sodium N-Octadecyl S...

    Sodium N-Octadecyl Sulfate is a marine derived natural products found in Aplidium turbinatum.

  • 8-Bromoguanosine

    8-Bromoguanosine is a brominated derivative of guanosine. It is activate lymphocytes through an intracellular mechanism to exert immunostimulatory effects.

  • Moracin P

    Moracin P exhibits potent in vitro inhibitory activity against hypoxia-inducible factor (HIF-1), which is a key mediator during adaptation of cancer cells to tumour hypoxia.